Efficacy and safety of treatment with biologicals ... | 合法藥品大搜索

由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review ... Read More

由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A ... Read More

由 K Yan 著作 · 2019 · 被引用 4 次 — Materials & methods: Eligible studies evaluated reslizumab and mepolizumab in patients with inadequately-controlled severe eosinophilic ast ... Read More

由 M Liddament 著作 · 2019 · 被引用 15 次 — Reslizumab and mepolizumab are recently approved monoclonal antibodies for the treatment of severe (uncontrolled) eosinophilic asthma. Both are effective in ... Read More

由 E Ridolo 著作 · 2020 · 被引用 3 次 — They include monoclonal antibodies that target the Th2-pathway cytokines, such as IL-5 (mepolizumab and reslizumab) or its receptor ( ... Read More

由 M Mukherjee 著作 · 2018 · 被引用 118 次 — ... IV reslizumab was superior to fixed-dose SC mepolizumab in ... of Δ between before and after treatment, mepolizumab vs. reslizumab, ... Read More

由 DP Henriksen 著作 · 2018 · 被引用 30 次 — Conclusions: Mepolizumab and reslizumab provide significant and clinically relevant improvements in exacerbation rate and OCS reduction. Read More

由 K Yan 著作 · 2019 · 被引用 4 次 — Reslizumab and mepolizumab are anti-IL5 biologics for the treatment of severe eosinophilic asthma. No head-to-head comparisons of the relative ... Read More

2017年9月21日 — By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab, reslizumab and benralizumab are new 'anti-IL-5' ... Read More

由 I Agache 著作 · 2020 · 被引用 57 次 — Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic ... Read More